Revolution Medicines, Inc.
RVMD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 19 sales; 697 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesRVMDW
Key figures
- Market capClose on Nov 10, 2026
- $41.8B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $78.4M in total
- 19
- 13F holdersQ2 2026, +183 vs. previous quarter
- 697
- 13F valueReported value at the end of Q2 2026
- $40.1B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- No comparable prior period
- Net income, FY2025
- -$1.13B
- No comparable prior period
- Free cash flow, FY2025
- -$913.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $197.6M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 13.1M
- Shares sold short
- Change
- +144.2K
- +1.1% vs. previous
- Days to cover
- 7.76
- At average daily volume
Superinvestors holding RVMD, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Revolution Medicines, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
1.7%
Revolution Medicines, Inc.'s share of the portfolio
- Shares
- 399,587
- Value
- $74.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Revolution Medicines, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2026 (view filing)6:00 PM ET | Oct 26 | 2 days | Mancini AnthonySee Remarks | SSale | −2.31K | $186.99 | −$431.9K | −5.5%39.8K after | 10b5-1 |
| Oct 1, 2026 (view filing)6:00 PM ET | Sep 29 | 2 days | Sandler Alan B.Chief Development Officer | SSale | −6.31K | $202.14 | −$1.28M | −10.7%52.6K after | 5 lots10b5-1 |
| Sep 29, 2026 (view filing)6:00 PM ET | Sep 25 | 4 days | Cislini JeffSVP & General Counsel | SSale | −765 | $207.32 | −$158.6K | −1.5%51.8K after | 10b5-1 |
| Sep 28, 2026 (view filing)6:00 PM ET | Sep 24-25 | 4 days | Mancini AnthonySee Remarks | SSale | −3.71K | $200.45 | −$743.3K | −8.5%39.8K after | 2 lots10b5-1 |
| Sep 24, 2026 (view filing)6:00 PM ET | Sep 22 | 2 days | Anderson Elizabeth MDirector | SSale | −10.1K | $193.04 | −$1.96M | −70.1%4.33K after | 5 lots10b5-1 |
| Sep 22, 2026 (view filing)6:00 PM ET | Sep 18 | 4 days | Mancini AnthonySee Remarks | SSale | −1.76K | $196.94 | −$347.4K | −4.2%40.4K after | 10b5-1 |
| Sep 18, 2026 (view filing)6:06 PM ET | Sep 16 | 2 days | Sandler Alan B.Chief Development Officer | SSale | −341 | $199.24 | −$67.9K | −0.6%52.9K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:05 PM ET | Sep 16 | 2 days | Mancini AnthonySee Remarks | SSale | −1.77K | $199.24 | −$353.4K | −4.0%42.1K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:04 PM ET | Sep 16 | 2 days | Kelsey Stephen MichaelSee Remarks | SSale | −5.57K | $199.24 | −$1.11M | −1.9%286.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:03 PM ET | Sep 16 | 2 days | Horn Margaret AChief Operating Officer | SSale | −4.97K | $199.24 | −$989.6K | −3.2%149.7K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 697 holdersThe largest institutional positions in Revolution Medicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,695,790 | $2.56B | 0.04% | +2,483,084+22.1% | Added |
| Farallon Capital Management, L.L.C. | 13,550,796 | $2.54B | 14.86% | −54,000−0.4% | Reduced |
| FMR LLC | 12,200,422 | $2.28B | 0.10% | +3,736,108+44.1% | Added |
| Baker Bros. Advisors LP | 11,443,357 | $2.14B | 10.74% | +1,888,000+19.8% | Added |
| Darwin Global Management, Ltd. | 10,629,822 | $2.05B | 54.45% | +8,418,804+380.8% | Added |
| Jupiter Topco LLC | 10,736,145 | $2.01B | 0.82% | +10,736,145 | New |
| Vanguard Capital Management LLC | 9,088,661 | $1.70B | 0.04% | +726,377+8.7% | Added |
| Vanguard Portfolio Management LLC | 8,294,855 | $1.55B | 0.07% | +792,232+10.6% | Added |
| Nextech Invest, Ltd. | 7,601,087 | $1.42B | 67.55% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 6,361,323 | $1.19B | 22.31% | −294,380−4.4% | Reduced |
Holders of 5% or more of RVMD
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Revolution Medicines, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. | 13G/A | 7.50%14.6M shares | −0.40 ppfrom 7.90% | Nov 9, 20236 filings | Feb 9, 2026 | SEC |
| FMR LLC | 13G/A | 7.20%15.4M shares | +2.20 ppfrom 5.00% | Feb 8, 20215 filings | Nov 5, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G/A | 6.40%13.6M shares | – | Aug 13, 20261 filing | Aug 13, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.70%12.2M shares | +1.20 ppfrom 4.50% | Jul 17, 20252 filings | Jul 29, 2026 | SEC |
| Baker Bros. Advisors LP | 13G | 5.30%11.4M shares | +0.40 ppfrom 4.90% | Aug 14, 20253 filings | Aug 14, 2026 | SEC |